Rosen Law Firm has filed a class action lawsuit on behalf of investors who sold or held Dun & Bradstreet (D&B) shares during its merger with Clearlake Capital Group from May to August 2025. The lawsuit alleges that D&B's merger disclosures were misleading, omitting key facts such as Executive Chairman Foley's personal interest in a quick sale and undervaluing the company. Investors who participated in the merger or held shares as of May 9, 2025, may be eligible for compensation. Those interested in joining the lawsuit must act by November 10, 2026. The case highlights concerns about transparency and fair valuation in corporate mergers.
Dun & Bradstreet Investors and the related securities fraud lawsuit provide context for market activity. For readers following Financials-sector stocks, here is Pluang's market snapshot as of Sep 16, 2026 01:02 WIB: Of 74 priced Financials-sector US stocks tradable on Pluang, 13 rose and 59 fell today. Notable prices include Morgan Stanley (MS) at USD 202.50, down 1.98%, Moody's Corporation (MCO) at USD 468.83, down 1.93%, and Oxford Lane Capital Corp (OXLC) at USD 9.36, down 1.89%.
At the 2026 Chery International User Summit, Chery introduced its Super Intelligent Valet Parking (SIVP) system, designed to simplify parking for families. The system uses advanced sensors and AI to enable features like One Tap Departure and One Step...
The Arbitrum Foundation announced operating rules for its Developer Guild, designating Offchain Labs as its first member. The guild will receive 3% of income from priority gas auctions and sequencer fast data streams on Arbitrum One, plus 2% of net p...
Margin debt in the US increased by 1.8% in September, reaching $1.48 trillion. This represents a 31.4% increase compared to the same month last year, or 26.7% when adjusted for inflation. The rise in margin debt indicates growing investor borrowing, ...
Zomedica held an investor webinar focusing on its clinical programs and evidence-based adoption of veterinary products. The company emphasized that veterinarians prefer products supported by published data, which Zomedica integrates into its three ma...
This week saw the debut of one biotech IPO, Lycia Therapeutics, which priced its upsized offering at the top of the range. Additionally, four companies filed initial IPO documents, including two significant biotech firms. Investors are closely watchi...
